The 1260 Infinity bio-inert quaternary liquid chromatography (LC) system from Agilent Technologies is designed to characterise and confirm large biomolecules,
It is especially targeted towards new biological entities (NBEs) and therapeutic monoclonal antibodies.
'This new system is a complete solution for addressing the growing demand to analyse NBEs and biosimilars, as drug developers seek to determine safety and efficacy of these complex molecules,' said Stefan Schuette, Agilent LC marketing director.
The system is based on the Agilent 1260 Infinity LC system with quaternary pump module.
It features a completely inert, metal-free sample-flow path and a stainless-steel-free solvent delivery path to protect sample integrity and minimise unspecific surface interaction and corrosion of the instrument.
The system tolerates a pH range from 1 to as high as 14.
Agilent also offers a range of BioHPLC ion-exchange and size-exclusion columns designed for these specific types of analyses, contributing to the robust, reproducible high-resolution performance.
The standard detector and the 600-bar power range combine to provide the lowest detection limits and highest resolution per time for any bio-inert LC-based bioseparation system, from low-pressure methods up through small-particle, high-pressure column technology.
The Agilent bio-inert LC system can accommodate bioanalysis and bio-purification tasks, offering analytical flow rates and fraction collection as high as 10ml/min.
